SCHEMBL5585490

SCHEMBL5585490

CN(Cc1ccc(C(=O)O)cc1)c1nc(-c2cccc(OCc3ccc(C4CCCCC4)cc3)c2)cs1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.41
MEN1 O00255 2/20 0.41
NPSR1 Q6W5P4 1/20 0.41
MRGPRX4 Q96LA9 1/20 0.41
CSNK2A1 P68400 1/20 0.40
CPT2 P23786 1/20 0.40
CPT1A P50416 1/20 0.40
USP30 Q70CQ3 2/20 0.40
UCHL1 P09936 1/20 0.40
RXRA P19793 1/20 0.39
RXRB P28702 1/20 0.39
RXRG P48443 1/20 0.39
TSHR P16473 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
PPARA Q07869 1/20 0.39
NR1H4 Q96RI1 1/20 0.39
STAT3 P40763 2/20 0.39
HTT P42858 1/20 0.39
CPB1 P15086 1/20 0.39
PTGES O14684 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5585668 0.91 SMN1; SMN2 (0.43) KMT2AMEN1NPSR1MRGPRX4CSNK2A1
SCHEMBL5585466 0.90 HRH3 (0.44) KMT2AMEN1NPSR1MRGPRX4CPT2
SCHEMBL5999838 0.90 HRH3 (0.44) KMT2AMEN1NPSR1MRGPRX4CPT2
SCHEMBL5585812 0.90 MEN1 (0.40) KMT2AMEN1NPSR1MRGPRX4CSNK2A1
SCHEMBL5585799 0.90 HRH3 (0.44) KMT2AMEN1NPSR1MRGPRX4CPT2
SCHEMBL5585509 0.90 HRH3 (0.44) KMT2AMEN1NPSR1MRGPRX4CPT2
Hydrochloric Acid SCHEMBL5585627 0.90 HRH3 (0.44) KMT2AMEN1NPSR1MRGPRX4CPT2
SCHEMBL5585491 0.88 MEN1 (0.40) KMT2AMEN1NPSR1MRGPRX4CSNK2A1
SCHEMBL5585540 0.88 MRGPRX4 (0.40) KMT2AMEN1NPSR1MRGPRX4CSNK2A1
SCHEMBL14601454 0.88 RXRA (0.42) KMT2AMEN1USP30RXRARXRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7163952-B2 Azole compound and medicinal use thereof JAPAN TOBACCO INC. (JP) 2007-01-16 US disclosed
US-7163952-B2 Azole compound and medicinal use thereof JAPAN TOBACCO INC. (JP) 2007-01-16 US disclosed
US-7163952-B2 Azole compound and medicinal use thereof JAPAN TOBACCO INC. (JP) 2007-01-16 US disclosed
US-20050065196-A1 Azole compound and medicinal use thereof JAPAN TOBACCO INC. (JP) 2005-03-24 US disclosed
EP-1452530-A1 AZOLE COMPOUND AND MEDICINAL USE THEREOF JAPAN TOBACCO INC. (JP) 2004-09-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050065196-A1 Azole compound and medicinal use thereof PTPN7, PTPN1, PTPN5 KMT2A 2589/4885MEN1 3299/4885NPSR1 369/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.